Treatment Action Group (TAG) is proud to present “What TB Treatment advocates need to Know about active TB Drug Safety Monitoring and Management and Pharmacovigilance (aDSM/PV)” on Tuesday, April 16 at 8:30 a.m. EST on Zoom.

In recent years, a new generation of shorter, all-oral, and effective medicines for drug-resistant tuberculosis (DR-TB) has been recommended by the World Health Organization (WHO). These alternative regimens, which are referred to as BPaL/M, BEAT, and endTB, are shorter and easier on patients than previous drug regimens that include multiple drugs with harsh side effects. However, newer forms of care require close attention to adverse side effects and harmful responses – also known as pharmacovigilance.

The webinar will provide TB advocates, people with TB, and community treatment supporters with the basics of monitoring and management of newer TB treatments, identifying common side effects, and recognizing patient safety during treatment. Presenters include Nathalie Lachenal, pharmacovigilance officer at Médecins Sans Frontières, and Mansa Mbenga, treatment and care team lead with KNCV Tuberculosis Foundation. The conversation will be moderated by Mike Frick, TB program co-director with TAG.

Register here.

Moderator:
Mike Frick, TB Project Co-Director, Treatment Action Group

Presenters:
Nathalie Lachenal, Médecins Sans Frontières
Mansa Mbenga, KNCV